Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Phase 4 Recruiting 580 enrolled Second Affiliated Hospital of Soochow University

RandomizedParallel-groupSingle-blindTreatment

Summary

This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.

Timeline

Start: 2025-08-30
Primary completion: 2027-02-28
Completion: 2027-05-31

Publications

Xu J, Peng H, Zhu Y, Xu F, Zhu L, Yang J, Kang T, Wang S, Yu X, Liu J, Wang P, Zhang M, Liu CF, Cao Y, Shi J. Tirofiban with sequential dual antiplatelet therapy in mild acute ischemic stroke (TiMIS): protocol for a multicenter, randomized controlled trial. Ann Med. 2026 Dec;58(1):2644698. doi: 10.1080/07853890.2026.2644698. Epub 2026 Mar 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirofiban	Other / unclassified	0.1 ug/kg	Intravenous
Comparator	Aspirin	Small molecule	100 mg	Oral
Comparator	Clopidogrel	Small molecule	75 mg	Oral

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Summary

Timeline

Publications

Drugs

Indications